🔎 Trials Near Me

Home › Cardiovascular Disease › Florida › Orlando

Cardiovascular Disease clinical trials in Orlando, FL

14 studies for Cardiovascular Disease are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

RecruitingPhase 2
  • Florida Institute For Clinical Research, LLC, Orlando
  • K2 Medical Research - Maitland, Maitland · 6 mi away
  • Omega Research Orlando, Altamonte Springs · 9 mi away
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07783802

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

RecruitingPhase 3
  • Clinical Site Partners, LLC dba Flourish Research, Winter Park · 5 mi away
Ages 45 to 80 · All sexes · Updated Sep 22, 2026 · NCT07613294

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

RecruitingPhase 3
  • Clinical Trial Site, Orlando
  • Clinical Trial Site, Winter Park · 5 mi away
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07181109

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

RecruitingPhase 3
  • Florida Institute for Clinical Research, Orlando
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07064473

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

RecruitingPhase 3
  • Clinical Research Site, Kissimmee · 16 mi away
Ages 18 to 85 · All sexes · Updated Sep 11, 2026 · NCT07816185

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

Recruiting
  • Advent Health, Orlando
Ages 18 to 100 · All sexes · Updated Sep 9, 2026 · NCT06310031

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

RecruitingPhase 2
  • Clinical Research Site, Kissimmee · 16 mi away
Ages 18 to 85 · All sexes · Updated Sep 2, 2026 · NCT07333183

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

RecruitingObservational study
  • Arnold Palmer Hospital for Children, Orlando
  • Nemours Children's Hospital, Orlando
Ages 7 and older · All sexes · Updated Aug 25, 2026 · NCT05705531

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

RecruitingPhase 3
  • Research Site, Orlando
  • Research Site, Orlando
  • Research Site, Orlando
  • and 2 more
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

RecruitingPhase 3
  • Clinical Site Partners Orlando dba Flourish Research, Winter Park · 5 mi away
Ages 50 to 105 · All sexes · Updated Aug 21, 2026 · NCT07136012

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

RecruitingPhase 3
  • FC Site Partners Miami, Winter Park · 5 mi away
Ages 18 to 80 · All sexes · Updated Aug 7, 2026 · NCT06813911

SPYRAL GEMINI Pilot Study

Recruiting
  • Orlando Health Heart & Vascular Institute, Orlando
Ages 18 to 80 · All sexes · Updated Jun 24, 2026 · NCT06907147

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

Recruiting
  • Advent Health Hospital, Orlando
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT03142152

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

RecruitingPhase 3
  • AdventHealth, Orlando
Ages 18 to 75 · All sexes · Updated Mar 24, 2026 · NCT06217302

Cardiovascular Disease trials in other cities

Other studies in Orlando

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.